Marksans Pharma Ltd — earnings calls

Marksans Pharma reported Q4 FY26 operating revenue of Rs 856 crores, up 20.8% year-on-year, with EBITDA margin expanding to 22.8% and profit after tax rising 64.3% to Rs 149 crores. For the full year, revenue crossed Rs 3,000 crores for the first time, reaching Rs 2,951 crores, with EBITDA margin at 20.4% and a year-end cash balance of Rs 990 crores. Management discussed raw material cost inflation linked to petroleum-related inputs and geopolitical disruption, alongside growth across North America, U.K., and Australia markets and new market entries in Germany, Canada and Ireland.